Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Accessed via the internet, the online self-help programme is for people who binge eat, particularly those with bulimia nervosa, binge eating disorder, and similar eating problems. It's designed for ...
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said. As Sam Roberts prepared to ...
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) TA1124 27 January 2026 27 January 2026 Pembrolizumab with pemetrexed and ...
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
There are simple discount patient access schemes for amivantamab (Rybrevant) and lazertinib (Lazcluze). NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS ...
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...
Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in ...
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) Draft guidance consultation NICE guideline 23 February 2026 Enfortumab vedotin with pembrolizumab for neoadjuvant ...
Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...
There is a simple discount patient access scheme for polatuzumab vedotin. Contact [email protected] for details. The recommendations in this guidance represent the view of NICE, arrived at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results